Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TOVX
stocks logo

TOVX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.500
-95.65%
--
--
-0.460
-70.32%
--
--
-0.420
-78.24%
Estimates Revision
Stock Price
Go Down
down Image
-40.30%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Theriva Biologics Inc (TOVX.A) is -0.12, compared to its 5-year average forward P/E of -1.18. For a more detailed relative valuation and DCF analysis to assess Theriva Biologics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.18
Current PE
-0.12
Overvalued PE
0.18
Undervalued PE
-2.54

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.02
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.15
Undervalued EV/EBITDA
-0.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

TOVX News & Events

Events Timeline

(ET)
2025-11-12
08:12:00
Theriva Biologics Announces Q3 Earnings Per Share of 45 Cents Compared to a Loss of $6.81 Last Year
select
2025-10-24 (ET)
2025-10-24
14:35:58
Theriva Biologics reports no significant changes to explain unusual trading activity.
select
2025-10-16 (ET)
2025-10-16
08:18:14
Theriva Biologics reveals $4M warrant inducement deal.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-12Yahoo Finance
Theriva Biologics: Overview of Q3 Earnings
  • Company Performance: Theriva Biologics, Inc. reported a loss of $4.4 million in its third quarter.
  • Earnings Per Share: The loss translates to 45 cents per share for the Rockville, Maryland-based company.
[object Object]
Preview
2.0
10-25Newsfilter
Theriva Biologics Addresses Uncommon Market Activity

  • Unusual Trading Activity: Theriva Biologics reported unusual trading activity in its common stock on October 24, 2025, but found no material developments or reasons for the market action.

  • VIRAGE Trial Presentation: The company recently presented expanded data from its VIRAGE trial investigating VCN-01 at the ESMO 2025 Annual Congress on October 13, 2025.

  • Company Overview: Theriva Biologics is a clinical-stage company focused on developing cancer therapeutics, including oncolytic adenoviruses and other treatments aimed at improving patient outcomes.

  • Lead Candidates: The company's lead candidates include VCN-01, SYN-004, and SYN-020, each targeting different aspects of cancer treatment and microbiome protection.

[object Object]
Preview
4.5
10-03Benzinga
Stock Market Update: Nasdaq and Dow Futures Rise on Third Day of Shutdown—Focus on Rumble, Rigetti, and Kodiak

  • Market Performance: U.S. stock futures rose on Friday, continuing the upward trend from Thursday, driven by AI optimism despite a government shutdown. Major indices like the Dow Jones, S&P 500, and Nasdaq all showed gains, with Nvidia reaching a record market cap of $4.6 trillion.

  • Investor Sentiment: A divergence in sentiment was noted between institutional and retail investors, with institutions selling off $4.7 billion in equities while retail investors took the opportunity to buy, indicating a potential cautionary signal for the market.

  • Economic Indicators: Key economic reports, including the U.S. employment report and services PMI, were delayed due to the government shutdown, while expectations for a Federal Reserve interest rate cut in October remain high.

  • Sector Highlights: Notable stock movements included significant gains for Actelis Networks and XCel Brands following contract announcements, while energy and consumer discretionary sectors faced losses.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Theriva Biologics Inc (TOVX) stock price today?

The current price of TOVX is 0.2416 USD — it has increased 20.99 % in the last trading day.

arrow icon

What is Theriva Biologics Inc (TOVX)'s business?

Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform. The Company’s candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci), and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.

arrow icon

What is the price predicton of TOVX Stock?

Wall Street analysts forecast TOVX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TOVX is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Theriva Biologics Inc (TOVX)'s revenue for the last quarter?

Theriva Biologics Inc revenue for the last quarter amounts to -4.44M USD, decreased -11.83 % YoY.

arrow icon

What is Theriva Biologics Inc (TOVX)'s earnings per share (EPS) for the last quarter?

Theriva Biologics Inc. EPS for the last quarter amounts to -4338000.00 USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Theriva Biologics Inc (TOVX)'s fundamentals?

The market is revising No Change the revenue expectations for TOVX for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -40.30%.
arrow icon

How many employees does Theriva Biologics Inc (TOVX). have?

Theriva Biologics Inc (TOVX) has 22 emplpoyees as of December 05 2025.

arrow icon

What is Theriva Biologics Inc (TOVX) market cap?

Today TOVX has the market capitalization of 8.23M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free